Therapeutics Related News

Cell Design Labs Announces Issuance of Broad Patent for Programmable Car-T Cells to Treat Cancer and Other Diseases

SAN FRANCISCO, Calif. – March 15, 2017 – Cell Design Labs, Inc. today announced the issuance of U.S. Patent No. 9,587,020, entitled, “Chimeric Antigen Receptor and Methods of Use Thereof.” This patent, issued to UC San Francisco (UCSF) and exclusively [...]

By | March 26th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

eGenesis Co-Founder Luhan Yang Named Young Global Leader by World Economic Forum

Cambridge, Mass. – March 15, 2017 – Co-founder and chief scientific officer, Luhan Yang, Ph.D., has been honored as a Young Global Leader with the class of 2017. This honor is granted by the World Economic Forum each year to [...]

By | March 20th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

eGenesis Announces $38 Million Series A Financing, Led by Biomatics Capital and ARCH Venture Partners, to Solve Shortage of Organs for Donation

Cambridge, Mass., March 16, 2017 — eGenesis, a biotechnology company focused on utilizing genome editing technology to make xenotransplantation a routine and lifesaving medical procedure, today announced that it raised a $38 million Series A financing co-led by Biomatics Capital [...]

By | March 20th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock

CAMBRIDGE, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 4,000,000 shares of its common stock at a price to the public of $22.50 [...]

By | March 20th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases

DUBLIN, Ireland and CAMBRIDGE, Mass., March 14, 2017 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and [...]

By | March 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health Assets

GERMANTOWN, Md., March 10, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Precigen, Inc., a wholly-owned [...]

By | March 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|